Date:2/7/2013

ments. Such statements are subject to certain risks and uncertainties, which could cause the company's actual results to differ materially from those anticipated by the forward-looking statements.  The most significant of these uncertainties are described in CareFusion's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: we may be unable to effectively enhance our existing products or introduce and market new products or may fail to keep pace with advances in technology; we are subject to complex and costly regulation; cost containment efforts of our customers, purchasing groups, third-party payers and governmental organizations could adversely affect our sales and profitability; current economic conditions have and may continue to adversely affect our results of operations and financial condition; we may be unable to realize any benefit from our cost reduction and restructuring efforts and our profitability may be hurt or our business otherwise might be adversely affected; we may be unable to protect our intellectual property rights or may infringe on the intellectual property rights of others; defects or failures associated with our products and/or our quality system could lead to the filing of adverse event reports, recalls or safety alerts and negative publicity and could subject us to regulatory actions; we are currently operating under an amended consent decree with the FDA and our failure to comply with the requirements of the amended consent decree may have an adverse effect on our business; and our success depends on our key personnel, and the loss of key personnel or the transition of key personnel, including our chief executive officer, could disrupt our business.  The CareFusion news release and the information contained herein reflect management's views as of Feb. 7, 2013. Except to the limited extent required by applicable law
'/>"/>

SOURCE CareFusion Corp. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Related medicine technology :

1. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
2. CareFusion Strengthens U.K. Presence With Acquisition of Medical Products Distributor
3. CareFusion Expands Infusion Pump Interoperability
4. CareFusion To Report Fourth Quarter And Fiscal 2012 Results On Aug. 9
5. CareFusion Reports Fourth Quarter and Fiscal 2012 Results
6. CareFusion Recognizes Best Of The Best U.S. Hospitals
7. CareFusion Provides Update On Form 10-K Filing
8. CareFusion To Report Preliminary Fiscal 2013 First Quarter Results On Nov. 8
9. CareFusion Reports Preliminary First Quarter Fiscal 2013 Results
10. CareFusion Launches New Preoperative Cleansing Program For In-Home Patient Use
11. CareFusion Files Fiscal 2012 Form 10-K